Influenza treatment options
Pro Research Analysisby 
Searched over 200M research papers
Antiviral Drugs for Influenza Treatment
Antiviral drugs are the main treatment option for influenza, especially for people who are severely ill or at high risk of complications. The most commonly used drugs are neuraminidase inhibitors (NAIs) such as oseltamivir, zanamivir, peramivir, and laninamivir. These drugs work by stopping the virus from spreading in the body and are most effective when started within 48 hours of symptom onset, leading to better outcomes and reduced mortality and hospitalization rates, especially in high-risk groups 15910. Baloxavir marboxil, a newer drug that targets a different part of the virus, is also effective and has been approved in several countries 2567+1 MORE.
Older drugs like amantadine and rimantadine were once used, but their effectiveness has been limited by the development of resistant virus strains 26. Among the newer options, baloxavir marboxil, zanamivir, and peramivir are preferred due to their high specificity and bioavailability .
Combination and Adjunctive Therapies
Combining antiviral drugs with different mechanisms of action is being studied as a way to improve outcomes and reduce the risk of resistance, especially in severe or immunocompromised patients 378. Some studies suggest that combination therapy may help, but more research is needed to confirm its benefits and safety 38. Adjunctive therapies, such as drugs that modulate the immune response, are also being explored for severe cases 38.
Antibody-Based and Next-Generation Treatments
Monoclonal antibodies that target the influenza virus, especially the hemagglutinin (HA) stalk, have shown promise in early clinical trials. These antibody-based therapies are safe and can reduce symptoms, and may become important options for prevention and treatment in the future 46. Other new drugs and direct-acting antivirals are in development, aiming to overcome resistance and improve effectiveness 67.
Special Considerations and Emerging Alternatives
While antiviral drugs are effective, the emergence of resistant virus strains is a concern, making it important to monitor for resistance and use these drugs appropriately 567. Nanotechnology is also being explored as a potential new approach for influenza treatment . For now, NAIs remain the first-line treatment, but careful patient selection and early initiation of therapy are key to maximizing benefits 5610.
Conclusion
The main treatment options for influenza are antiviral drugs, especially neuraminidase inhibitors and the newer baloxavir marboxil. Early treatment is crucial for the best outcomes. Combination therapies, antibody-based treatments, and new drug classes are being developed to address resistance and improve care, but more research is needed to determine their full potential. Monitoring for resistance and using antivirals wisely remain important in managing influenza.
Sources and full results
Most relevant research papers on this topic